- Home
- EGBN vs IGMS Comparison
EGBN vs IGMS Comparison
Compare EGBN & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGBN
- IGMS
- Stock Information
- Founded
- EGBN 1997
- IGMS 1993
- Country
- EGBN United States
- IGMS United States
- Employees
- EGBN N/A
- IGMS N/A
- Industry
- EGBN Major Banks
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- EGBN Finance
- IGMS Health Care
- Exchange
- EGBN Nasdaq
- IGMS Nasdaq
- Market Cap
- EGBN 862.0M
- IGMS 528.6M
- IPO Year
- EGBN 1998
- IGMS 2019
- Fundamental
- Price
- EGBN $29.41
- IGMS $8.89
- Analyst Decision
- EGBN Hold
- IGMS Hold
- Analyst Count
- EGBN 2
- IGMS 8
- Target Price
- EGBN $25.50
- IGMS $14.63
- AVG Volume (30 Days)
- EGBN 246.1K
- IGMS 247.6K
- Earning Date
- EGBN 10-23-2024
- IGMS 11-08-2024
- Dividend Yield
- EGBN 5.15%
- IGMS N/A
- EPS Growth
- EGBN N/A
- IGMS N/A
- EPS
- EGBN N/A
- IGMS N/A
- Revenue
- EGBN $242,057,000.00
- IGMS $2,918,000.00
- Revenue This Year
- EGBN N/A
- IGMS $298.54
- Revenue Next Year
- EGBN $4.02
- IGMS N/A
- P/E Ratio
- EGBN N/A
- IGMS N/A
- Revenue Growth
- EGBN N/A
- IGMS 57.64
- 52 Week Low
- EGBN $15.99
- IGMS $4.72
- 52 Week High
- EGBN $31.97
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- EGBN 64.44
- IGMS 28.73
- Support Level
- EGBN $28.00
- IGMS $8.58
- Resistance Level
- EGBN $29.02
- IGMS $10.08
- Average True Range (ATR)
- EGBN 1.00
- IGMS 1.41
- MACD
- EGBN -0.11
- IGMS -0.49
- Stochastic Oscillator
- EGBN 82.14
- IGMS 6.46
About EGBN Eagle Bancorp Inc.
Eagle Bancorp Inc is a bank holding company that operates through its wholly-owned subsidiary, EagleBank which offers a broad range of commercial banking services to business and professional clients, and consumer banking services to individuals. These services include commercial loans for a variety of business purposes such as for working capital, equipment purchases, real estate lines of credit and government contract financing, asset-based lending and accounts receivable financing, construction and commercial real estate loans, business equipment financing, consumer home equity lines of credit, personal lines of credit and term loans, consumer loans, personal credit cards, residential mortgage loans.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.